Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07115-3 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Xin Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority's Ascent Plan, Capital's Funds for Health Improvement and Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research…
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Beijing, 100142, China.
- Department of Nuclear Medicine, Affiliated Hospital of Hubei, Xiangyang Central Hospital, University of Arts and Science, Xiangyang, 441138, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
- Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, No.38 Xueyuan Rd, Beijing, 100191, China. jiabing@bjmu.edu.cn.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Beijing, 100142, China.…
ORCID-Profile: Nan Li
Förderung
- National Natural Science Foundation of China
- Beijing Hospitals Authority's Ascent Plan
- Capital's Funds for Health Improvement and Research
- Beijing Research Ward Excellence Program
- National Key Research and Development Program
- Beijing Natural Science Foundation
- Science Foundation of Peking University Cancer Hospital
- National Ten-thousand Talent Program
Zitieren
APA
Zhou, X., Yan, S., Ma, X., Zhu, H., Liu, B., Yang, X., Jia, B., Yang, Z., Wu, N., & Li, N. (2025). Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07115-3
Vancouver
Zhou X, Yan S, Ma X, Zhu H, Liu B, Yang X, et al. Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07115-3
BibTeX
@article{Zhou2025,
author = {Zhou, Xin and Yan, Shi and Ma, Xiaopan and Zhu, Hua and Liu, Bing and Yang, Xin and Jia, Bing and Yang, Zhi and Wu, Nan and Li, Nan},
title = {Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07115-3}
}
EUVIMED